hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06276582, orgStudyIdInfo id: 519379-2, briefTitle: Screening for Neonatal Jaundice With a Mobile Health Device: a Validation Study in Oaxaca, Mexico., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-17, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Norwegian University of Science and Technology, class: OTHER, collaborators name: Picterus AS, collaborators name: Instituto Mexicano del Seguro Social, descriptionModule briefSummary: The performance and accuracy of the smartphone application (app) Picterus Jaundice Pro (PicterusJP) will be validated by a cross-sectional study conducted in low resource settings in Mexico. Physics-based and machine learning-based models will be used to analyze the images obtained with the app and its performance will be compared., conditionsModule conditions: Jaundice, Neonatal, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Screening for neonatal jaundice with a mobile health device, outcomesModule primaryOutcomes measure: Enable high qualitative estimation of bilirubin levels in the blood of Mexican newborns using Picterus JP, secondaryOutcomes measure: Correlation between bilirubin measurements with Picterus JP and total serum bilirubin, otherOutcomes measure: Accuracy of Picterus JP to screen for neonatal jaundice, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 14 Days, stdAges: CHILD, contactsLocationsModule locations facility: Hospital General de Zona 1, status: RECRUITING, city: Oaxaca, zip: 68040, country: Mexico, contacts name: Rey Manuel Silva Mendez, role: CONTACT, phone: +529511283520, email: reymsilvam@gmail.com, geoPoint lat: 17.06542, lon: -96.72365, hasResults: False
protocolSection identificationModule nctId: NCT06276569, orgStudyIdInfo id: 2023-LCYJ-MS-26, briefTitle: Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Respiratory Distress Syndrome After Cardiac Surgery :a Single Centre Random Control Trial., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-18, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, class: OTHER, descriptionModule briefSummary: The aim of this study is to assess the effectiveness and safety of sivelestat sodium in preventing acute respiratory distress syndrome (ARDS) following cardiac surgery, with the objective of providing evidence-based support for its clinical application., conditionsModule conditions: Cardiac Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 384, type: ESTIMATED, armsInterventionsModule interventions name: Sivelestat, interventions name: placebo, outcomesModule primaryOutcomes measure: Oxygenation index, primaryOutcomes measure: Inflammatory index, primaryOutcomes measure: Myocardial injury marker, primaryOutcomes measure: Acute physiology and chronic health evaluation(APACHE II) socre, primaryOutcomes measure: Murray socre, primaryOutcomes measure: ICU time, primaryOutcomes measure: In-hospital time, primaryOutcomes measure: 30-day all-cause mortality, primaryOutcomes measure: 90-day all-cause mortality, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06276530, orgStudyIdInfo id: APHP231036, briefTitle: Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling, acronym: VaPosVent, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: This study aims to identify physiopathologic mechanisms related to surgical approaches during lobectomies for non-small cell lung cancer which can explain the better quality of life and the decrease of of post-operative complications in minimally invasive techniques (video-assisted thoracic surgery and robotic-assisted thoracic surgery) compared to conventional thoracotomy., conditionsModule conditions: Resectable Lung Non-Small Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: EOS imaging for musculoskeletal disorder, interventions name: Movement analysis by an optoelectronic camera., interventions name: Stabilometric measurement by strength platform, outcomesModule primaryOutcomes measure: Thoracic kyphosis (T1- T12 angle) and vertical alignment head-pelvis and head- C7 vertebra (angle OD-HA and OD-C7) (EOS), secondaryOutcomes measure: Width of rib cage (EOS), secondaryOutcomes measure: Rib cage volume (EOS), secondaryOutcomes measure: " Umbrella "angle (EOS), secondaryOutcomes measure: Center of Pressure displacement (Optoelectronic system), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Thoracic and Vascular Surgery Tenon University Hospital, city: Paris, zip: 75020, country: France, contacts name: Harry ETIENNE, M.D., PhD, role: CONTACT, phone: +33 6 67 96 82 89, email: h.etienne@hotmail.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06276517, orgStudyIdInfo id: APHP220918, secondaryIdInfos id: 2022-A01739-34, type: OTHER, domain: IDRCB, briefTitle: Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom, acronym: HIDDEN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2028-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Descriptive observational study in patients with spontaneous subarachnoid hemorrhage or following aneurysmal rupture to assess the presence of a post-HSA syndrome at 3 months, 6 months and 1 year, and its impact on functional outcome using the Rivermead questionnaire, conditionsModule conditions: Intracranial Hemorrhages, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: questionnaire, interventions name: SS-QoL, interventions name: SF-36, interventions name: CIQ-R, interventions name: BREFF, interventions name: MoCA, interventions name: IADL, interventions name: mMRS, interventions name: PCL-5, interventions name: Brief-Cope, outcomesModule primaryOutcomes measure: Evaluate the presence of post SAH syndrome at 3 months and its impact on return to work using the Rivermead Post-Concussion symptoms questionnaire (RPQ), and its impact on functional outcome., secondaryOutcomes measure: - study the factors determining the presence of a post-HSA syndrome and an inability to return to work at 3 months, 6 months and 1 year, secondaryOutcomes measure: To study the prevalence of post-traumatic stress in this population, secondaryOutcomes measure: Study patients' coping strategies in relation to functional recovery using the Brief-Cope self-questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276491, orgStudyIdInfo id: XmAb541-01, briefTitle: Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Xencor, Inc., class: INDUSTRY, descriptionModule briefSummary: The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes., conditionsModule conditions: Ovarian Cancer, conditions: Endometrial Cancer, conditions: Germ Cell Tumor, conditions: Testicular Germ Cell Tumor, conditions: Ovarian Germ Cell Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: Dose escalation and expansion study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 212, type: ESTIMATED, armsInterventionsModule interventions name: XmAb541, outcomesModule primaryOutcomes measure: Incidence of Adverse Events, primaryOutcomes measure: Incidence of dose-limiting toxicities (DLTs), primaryOutcomes measure: Incidence of cytokine release syndrome (CRS), secondaryOutcomes measure: Measurement of Cmax, secondaryOutcomes measure: Measurement of area under curve (AUC), secondaryOutcomes measure: Measurement of Ctrough, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Duration of Response, secondaryOutcomes measure: Changes in Circulating Tumor DNA (ctDNA), eligibilityModule sex: ALL, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Montefiore Einstein Comprehensive Cancer Center, status: RECRUITING, city: Bronx, state: New York, zip: 10461, country: United States, geoPoint lat: 40.84985, lon: -73.86641, hasResults: False
protocolSection identificationModule nctId: NCT06276452, orgStudyIdInfo id: 23.0434, secondaryIdInfos id: U2CDA050097, type: NIH, link: https://reporter.nih.gov/quickSearch/U2CDA050097, briefTitle: Supporting Resilience Among Re-entered Seniors, acronym: SRRS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-09, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Louisville, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: The first goal (Aim 1) of this clinical trial is to learn about specific strengths, challenges, and desired areas of knowledge and skill-building among older adults who re-entered their communities from a period of incarceration and to then develop a new psychoeducational intervention tailored to these older adults. The second goal (Aim 2) of this clinical trial is to test if the intervention increases chronic disease management and whether the intervention is considered appropriate and acceptable by older adults who re-entered their communities from a period of incarceration.Aim 1 participants will:* complete a baseline survey* participate in a focus groupAim 2 participants will:* complete a baseline survey* participate in an 8-week once weekly intervention* complete three follow up surveys, conditionsModule conditions: Chronic Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: Psychoeducation, outcomesModule primaryOutcomes measure: Chronic disease self managment, eligibilityModule sex: MALE, minimumAge: 45 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: New Legacy Reentry, status: RECRUITING, city: Louisville, state: Kentucky, zip: 40203, country: United States, contacts name: Stephanie Grace Prost, PhD, role: CONTACT, email: stephanie.prost@louisville.edu, geoPoint lat: 38.25424, lon: -85.75941, hasResults: False
protocolSection identificationModule nctId: NCT06276439, orgStudyIdInfo id: IRB23-0314, briefTitle: Intraoperative Imaging of Lymph Nodes, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2026-02-19, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Urbana-Champaign, class: OTHER, collaborators name: U.S. National Science Foundation, collaborators name: Ss. Cyril and Methodius University of Skopje, Macedonia, descriptionModule briefSummary: One-third of the global population battles cancer, with surgery being the primary treatment for localized forms. Successful treatment often hinges on the thorough removal of primary tumors and pinpointing cancerous sentinel lymph nodes (SLN). Although modern surgical imaging and fluorescent probes enhance the detection of sentinel lymph nodes using near-infrared (NIR) fluorescence, their inability to precisely determine the nodes' status can result in additional surgeries, lymphedema, and a reduced quality of life for patients. Our research direction aims to harness the potential of bioinspired imaging technologies with the goal of precisely identifying SLN status and ensuring only the cancerous lymph nodes are excised during the initial procedure. To realize this objective, we're drawing inspiration from the mantis shrimp's visual system to create a single-chip multispectral camera that spans the deep ultraviolet to the near-infrared spectrum. Our pioneering sensor seamlessly combines perovskite nanocrystals, optical filters, and vertically-aligned photodetectors on a single chip, enabling concurrent imaging of external NIR fluorophores and internal UV fluorescence from tumor-specific markers., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Surgical removal of breast cancer and lymph nodes, outcomesModule primaryOutcomes measure: Positive lymph node detection with custom sensors, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Clinic Hospital, status: RECRUITING, city: Skopje, zip: 1000, country: North Macedonia, contacts name: Viktor Gruev, PhD, role: CONTACT, phone: +1.267.847.4020, email: vgruev@illinois.edu, contacts name: Goran Kondov, MD, PHD, role: CONTACT, phone: +389 70 252010, email: kondov@yahoo.com, geoPoint lat: 41.99646, lon: 21.43141, hasResults: False
protocolSection identificationModule nctId: NCT06276426, orgStudyIdInfo id: 24468, briefTitle: Plants Optimizing Development Study (PODS), acronym: PODS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Urbana-Champaign, class: OTHER, collaborators name: Soy Nutrition Institute, descriptionModule briefSummary: This study aims to conduct a randomized clinical trial to measure the effects of a 3-month daily mixed-soy food intervention vs. a control group receiving isocaloric foods on reproductive hormones, body composition, metabolic risk, fecal microbiota, and cognition among 8-11-year-old children. Additionally, this study will assess soy food intake immediately following participation in the clinical trial to determine changes in soy food acceptance in children., conditionsModule conditions: Healthy Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 96, type: ESTIMATED, armsInterventionsModule interventions name: Soy foods, interventions name: Non-Soy Plant-Based Foods, outcomesModule primaryOutcomes measure: Sex steroid excretion, secondaryOutcomes measure: Gut microbiota, secondaryOutcomes measure: Attentional Accuracy, secondaryOutcomes measure: Attentional Reaction Time, secondaryOutcomes measure: Hippocampal-dependent Relational memory, secondaryOutcomes measure: Body Composition, secondaryOutcomes measure: Metabolic Markers, secondaryOutcomes measure: Pubertal Staging, secondaryOutcomes measure: Cognitive Abilities and Academic Achievement, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 11 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Illinois, status: RECRUITING, city: Urbana, state: Illinois, zip: 61801, country: United States, contacts name: Naiman Khan, PhD, RD, role: CONTACT, phone: 217-300-2197, email: nakhan2@illinois.edu, contacts name: Naiman Khan, PhD, RD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.11059, lon: -88.20727, hasResults: False
protocolSection identificationModule nctId: NCT06276413, orgStudyIdInfo id: REBRA, secondaryIdInfos id: REBRA, type: REGISTRY, domain: REBRA, briefTitle: REgistRy BRAnch goRE EndopRosthEsis, acronym: REBRA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: University Hospital Padova, class: OTHER, descriptionModule briefSummary: Multicenter registry on patients treated by the new Gore thoracic branched endoprosthesis, conditionsModule conditions: Aortic Aneurysm, Thoracic, conditions: Aortic Dissection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: GORE TAG Thoracic Branch Endoprosthesis, outcomesModule primaryOutcomes measure: early mortality, primaryOutcomes measure: device stability, primaryOutcomes measure: technical success, secondaryOutcomes measure: early major adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vascular and Endovascular Clinic - Padova University, city: Padova, zip: 35020, country: Italy, contacts name: Michele Piazza, Pr, role: CONTACT, phone: 3498644688, email: michele.piazza@unipd.it, geoPoint lat: 45.40797, lon: 11.88586, hasResults: False
protocolSection identificationModule nctId: NCT06276374, orgStudyIdInfo id: SMC 2023-12-107, briefTitle: Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-11-30, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Woo-Keun Seo, class: OTHER, descriptionModule briefSummary: To compare the safety of dual antiplatelet therapy with aspirin and clopidogrel and single antiplatelet therapy administered from 30 days to 12 months following carotid artery stenting on clinically significant bleeding and its prevention effects on net clinical events including combined cardiovascular and cerebrovascular accidents and major bleeding events in patients with carotid artery disease who are at high bleeding risk., conditionsModule conditions: Carotid Artery Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1556, type: ESTIMATED, armsInterventionsModule interventions name: Patients who are scheduled to undergo carotid artery stenting, outcomesModule primaryOutcomes measure: Clinically significant bleeding, secondaryOutcomes measure: Combined cardiovascular and cerebrovascular accidents, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276361, orgStudyIdInfo id: ROV-QUAR-2023-01, briefTitle: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia, acronym: QUARTZ, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-26, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Rovi Pharmaceuticals Laboratories, class: INDUSTRY, descriptionModule briefSummary: This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia., conditionsModule conditions: Schizophrenia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, interventions name: Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, interventions name: Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, interventions name: Oral risperidone; QUAR F1/2, Dose 3 - Deltoids, outcomesModule primaryOutcomes measure: λz, primaryOutcomes measure: t1/2, primaryOutcomes measure: Tmax, primaryOutcomes measure: Cmax, primaryOutcomes measure: Cmin, primaryOutcomes measure: Clast, primaryOutcomes measure: AUC0-t, primaryOutcomes measure: AUCinf, primaryOutcomes measure: AUCextrap, primaryOutcomes measure: Vd/F, primaryOutcomes measure: Cl/F, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Investigational Site, status: RECRUITING, city: Amman, country: Jordan, geoPoint lat: 31.95522, lon: 35.94503, hasResults: False